Comparison of Humira biosimilars in the US and Europe
The US biosimilars market is notably underdeveloped and biosimilar entry in the US has been difficult, consistently lagging behind Europe.
Pricing and Market Access
Economic unrest results in an average pharmaceutical price trend of 1,123% in Lebanon
Colombian healthcare reform aims to upend insurance and shift focus to primary care
Risk-sharing agreements are growing at a rate of 24%
Pharma sector reels as UK Government doubles VPAS payback rate on NHS drugs
Inflationary storm clouds will continue to buffet global pharma industry in 2023
Medicines priced under the early access programme in France see prices drop by 16%
US midterm election results have multiple implications for the pharma industry
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
